TD Cowen raised the firm’s price target on Addus HomeCare to $128 from $119 and keeps a Buy rating on the shares. The firm said with the Medicaid Access Rule finalized, the company can focus on building out clinical capabilities in Personal Care markets and entering new geographies and is now well positioned to capitalize on multiple growth fronts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus HomeCare price target raised to $135 from $127 at BofA
- Addus Homecare Expands Footprint with Gentiva Acquisition
- Addus HomeCare management to meet virtually with Stephens
- Addus HomeCare to acquire personal care operations of Gentiva for $350M
- Addus HomeCare price target raised to $130 from $118 at Oppenheimer